Halozyme Therapeutics, Inc. $HALO Stock Holdings Increased by Faithward Advisors LLC

Faithward Advisors LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 174.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 63,403 shares of the biopharmaceutical company’s stock after acquiring an additional 40,333 shares during the quarter. Faithward Advisors LLC’s holdings in Halozyme Therapeutics were worth $4,098,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of HALO. Measured Wealth Private Client Group LLC raised its stake in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC grew its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC grew its position in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares in the last quarter. Harbour Investments Inc. increased its stake in Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at about $70,000. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on HALO shares. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $53,030,564.60. This represents a 1.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the sale, the director directly owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,250 shares of company stock valued at $6,299,746 in the last quarter. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $69.62 on Wednesday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm’s 50 day moving average is $68.10 and its 200-day moving average is $68.69. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The stock has a market capitalization of $8.26 billion, a P/E ratio of 25.04, a P/E/G ratio of 0.29 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.